Evidence map›Paper›PMID 34150583›Full record

ReviewAnesthesiology and pain medicine2020

Utilization of Intravenous Lidocaine Infusion for the Treatment of Refractory Chronic Pain.

Janell Tully, Jai Won Jung, Anjana Patel, Alyson Tukan, Sameer Kandula, Allen Doan, Farnad Imani, Giustino Varrassi, Elyse M Cornett, Alan David Kaye and 2 more

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Anesthesiology and pain medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Dorsal Root Ganglion (DRG) and Chronic Pain.Anesthesiology and pain medicine · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 3 countries.

Janell TullyCollege of Medicine-Phoenix, University of Arizona, Phoenix, AZ, USA.
Jai Won JungSchool of Medicine, Georgetown University, Washington, DC, USA.
Anjana PatelSchool of Medicine, Georgetown University, Washington, DC, USA.
Alyson TukanCollege of Medicine-Phoenix, University of Arizona, Phoenix, AZ, USA.
Sameer KandulaCollege of Medicine-Phoenix, University of Arizona, Phoenix, AZ, USA.
Allen DoanCollege of Medicine-Phoenix, University of Arizona, Phoenix, AZ, USA.
Farnad ImaniPain Research Center, Department of Anesthesiology and Pain Medicine, Iran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0003-0814-0772
Giustino VarrassiPaolo Procacci Foundation, Roma, Italy.ORCID https://orcid.org/0000-0002-3822-2923
Elyse M CornettDepartment of Anesthesiology, LSU Health Shreveport, Shreveport, LA, USA.
Alan David KayeDepartment of Anesthesiology, LSU Health Shreveport, Shreveport, LA, USA.
Omar ViswanathDepartment of Anesthesiology, LSU Health Shreveport, Shreveport, LA, USA.ORCID https://orcid.org/0000-0002-6124-7037
Ivan UritsDepartment of Anesthesiology, LSU Health Shreveport, Shreveport, LA, USA.ORCID https://orcid.org/0000-0002-3652-6085
University of Arizona · USGeorgetown University · USLouisiana State University Health Sciences Center Shreveport · USCreighton University · USFondazione Roma · ITIran University of Medical Sciences · IRSouthCoast Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextChronic pain accounts for one of the most common reasons patients seek medical care. The financial burden of chronic pain on health care is seen by direct financial cost and resource utilization. Many risk factors may contribute to chronic pain, but there is no definite risk. Managing chronic pain is a balance between maximally alleviating symptoms by utilizing a therapeutic regimen that is safe for long-term use. Currently, non-opioid analgesics, NSAIDs, and opioids are some of the medical treatment options, but these have numerous adverse effects and may not be the best option for long-term use. However, Lidocaine can achieve both central and peripheral analgesic effects with relatively few side effects, which may be an ideal compound for managing chronic pain. EVIDENCE ACQUISITION: This is a Narrative Review.

resultsInfusion of lidocaine (2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide), an amino-amide compound, is emerging as a promising option to fill the therapeutic void for treatment of chronic pain. Numerous studies have outlined dosing protocols for lidocaine infusion for the management of perioperative pain, outlined below. While there are slight variations in these different protocols, they all center around a similar dosing regimen to administer a bolus to reach a rapid steady state, followed by infusion for up to 72 hours to maintain the therapeutic analgesic effects.

conclusionsLidocaine may be a promising pharmacologic solution with a low side effect profile that provides central and peripheral analgesia. Even though the multifaceted mechanism is not entirely understood yet, lidocaine may be a promising novel remedy in treating chronic pain in various conditions.

Indexed as

Chronic PainCRPSFibromyalgiaHeadacheLidocaineLow Back Pain

Identifiers

PMID34150583
PMCPMC8207879
OpenAlexW3118274105

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.